The Complete Guide to Boswellia Supplements UK
Scarlett Gray
BNutrDiet (Hons), APD, SDA
Reviewed by Scarlett Gray · About Scarlett
Accredited Practising Dietitian with Dietitians Australia (APD200526). Accredited Sports Dietitian and Credentialled Eating Disorder Clinician. First Class Honours in Nutrition and Dietetics from the University of Newcastle.
Reviewed by Scarlett Gray, Accredited Practising Dietitian (APD200526), BNutrDiet Hons, Sports Dietitian. @scarlett__redefiningnutrition
Reviewed: 16 September 2026
Boswellia serrata is one of the more interesting botanical ingredients in the joint health space: used in traditional medicine for thousands of years, and now the subject of a growing body of clinical research. It's also widely misunderstood, and widely oversold. This guide covers what Boswellia is, what the trials actually show, why the form you take matters, and where it fits in a sensible joint routine.
One challenge with Boswellia is that its key active compounds, the boswellic acids, particularly AKBA, have poor oral bioavailability from standard powdered extracts. Several enhanced formulations (phytosomes, AKBA-enriched extracts, lipid-based carriers) have been developed to improve absorption and have performed better in osteoarthritis trials than crude extracts. We'll come back to why that matters when choosing a supplement.
What is Boswellia serrata?
Boswellia serrata is a tree native to India, Northern Africa and the Middle East. Its bark produces a resin, known as frankincense, that has been used across Ayurvedic, traditional Chinese and Middle Eastern medicine for thousands of years, primarily for joint and inflammatory complaints.
Modern research has identified the compounds behind its activity: boswellic acids, of which AKBA (3-O-acetyl-11-keto-β-boswellic acid) is the most studied. AKBA inhibits 5-LOX (5-lipoxygenase), an enzyme involved in producing leukotrienes, which are mediators of the inflammatory processes associated with joint pain, swelling and stiffness.
The human evidence is genuinely encouraging for joints. A meta-analysis of seven randomised controlled trials covering 545 patients found that Boswellia supplementation produced significant reductions in pain, stiffness and functional impairment in osteoarthritis compared with controls, with a recommended minimum treatment duration of four weeks. The same body of research includes a systematic review of seven RCTs reporting encouraging results in other inflammatory conditions, including asthma, rheumatoid arthritis, Crohn's disease and collagenous colitis, though the quality of those trials was variable, so results there should be read cautiously. Boswellia is a supplement being researched for these conditions, not a treatment for any of them.
Why standard Boswellia supplements can fall short
The fundamental challenge with Boswellia supplementation is bioavailability. AKBA, the compound thought to drive the most clinical benefit, is a fat-soluble compound that doesn't mix well with water, which makes it hard for the body to absorb from standard Boswellia extracts. Studies comparing blood levels of AKBA after standard and enhanced formulations have shown that, with conventional supplements, a significant proportion of the AKBA never reaches the bloodstream in meaningful amounts.
This means many Boswellia supplements on the UK market might not deliver the amount the label suggests: the milligrams shown may look right, but if those milligrams come from a form the body struggles to absorb, less of the active compound gets where it needs to go. Enhanced formulations, such as phytosomes and AKBA-enriched extracts, have been specifically designed to get around this absorption problem and have shown better clinical results than standard extracts in studies of joint pain.
AprèsFlex®: an AKBA-enriched extract
AprèsFlex® is a patented Boswellia serrata extract developed to address the bioavailability limitation, and it's the form we use in Kollo Flex+. According to its published research, AprèsFlex® achieves 52% greater bioavailability than standard Boswellia extract [SUPPLIER STUDY LINK], and it is standardised to 20% AKBA, meaning each dose contains a consistent, specified concentration of the most studied boswellic acid rather than the variable and often unspecified AKBA content of generic extracts.
For context on what to look for generally: the Arthritis Foundation's guidance on Boswellia highlights AKBA-enriched extracts, such as 5-Loxin®, and advises checking that AKBA is specified on the label [AF LINK]. AprèsFlex® is one such AKBA-enriched, label-specified extract.
What the clinical research shows
AprèsFlex® has been studied in independent clinical trials for joint pain and mobility. Reported findings include improvements in joint pain and mobility in as little as 5 to 7 days [SUPPLIER STUDY LINK], which is faster than the four-week minimum typically seen with standard extracts, and statistically significant reductions in pain, stiffness and physical function scores compared with placebo [SUPPLIER STUDY LINK]. Laboratory research also suggests AKBA inhibits MMP (matrix metalloproteinase) enzymes involved in cartilage breakdown, though this mechanism evidence comes from lab studies rather than human outcomes.
As with all supplement research, these are study findings in study populations: individual results vary, and Boswellia is not a treatment for osteoarthritis or any joint condition.
Boswellia vs turmeric: which is better?
Turmeric (curcumin) and Boswellia are the two most commonly compared botanical ingredients for joint health, and both face the same core challenge: their active compounds are poorly absorbed in standard form. They work differently: AKBA inhibits 5-LOX, targeting leukotriene-driven inflammation that's particularly relevant to joint tissue, while curcumin acts more broadly on pathways including NF-kB and COX-2. There's no need to declare a single winner; the honest answer is that both have supportive evidence in osteoarthritis research, the form and absorption of either matters more than the headline ingredient, and joint-focused formulas often pair 5-LOX-targeting Boswellia with complementary ingredients rather than relying on one botanical alone.
Boswellia in Kollo Flex+
Kollo Flex+ delivers AprèsFlex® in its inner capsule alongside Univestin®, a patented blend of Chinese Skullcap and Cutch Tree extracts targeting both COX-2 and 5-LOX enzymes, a combination backed by a body of clinical studies [SUPPLIER STUDY LINK]. The outer liquid capsule adds black seed oil (898mg), vitamin D3 (2,000 IU) and vitamin K2 MK-7 (200μg); vitamin D contributes to the maintenance of normal bones and normal muscle function, and K2 contributes to the maintenance of normal bones. It's a thorough formula, and we'd rather show you what's in it and why than shout superlatives at you: explore Kollo Flex+ and judge the label for yourself.
As with any supplement, consult your GP if you are on medication or have existing health conditions. Boswellia was generally well tolerated in clinical trials, but food supplements are not a substitute for medical treatment: if you have persistent joint pain, get it properly assessed rather than self-managing with supplements, and never stop or replace prescribed medication without medical advice. Not recommended during pregnancy or breastfeeding without professional guidance.
Looking at the bigger picture? Read our guide to the best supplements for women over 40 [LINK], covering collagen, joint support, menopause and more.
